Study on the efficacy and safety of oral administration of Wuling Capsules in patients with metabolic dysfunction-associated fatty liver disease
Objective To explore the efficacy and safety of oral administration of Wuling Capsules in patients with metabolic dysfunction-associated fatty liver disease(MAFLD).Methods A total of 220 patients with MAFLD treated from January 2020 to January 2023 were included and divided into control group(110 cases)and experimental group(110 cases)by random number table method.The both groups received dietary intervention and aerobic exercise.On this basis,the control group took Hugan Tablets orally,while the experimental group took Wuling Capsules orally.The therapeutic effects and the occurrence of adverse reactions during the treatment were observed in the 2 groups.The changes of clinical symptoms,liver function,controlled attenuation parameters(CAP)and body mass index(BMI)before and after treatment in the 2 groups were statistically analyzed.Results After treatment,the total effective rate of the experimental group was higher than that of the control group(87.27%vs.73.64%,P<0.05),and the improvement of clinical symptoms(swelling and pain in the ribs,poor appetite,fatigue,abdominal distension and belching)was significantly better than that of the control group(P<0.05).After treatment,the CAP,alanine aminotransferase(ALT),and aspartate aminotransferase(AST)liver function indexes in both groups decreased(P<0.05),and the decrease in the experimental group was greater than that in the control group(P<0.05).After treatment,the decrease in BMI in the experimental group was greater than that in the control group(P<0.05).During the treatment,all patients in the 2 groups had good vital signs,and the adverse reactions were all general adverse events.All patients could tolerate and continue the treatment,and there was no significant difference in the incidence of adverse reactions(P>0.05).Conclusion Wuling Capsules can significantly improve the clinical symptoms and liver function indicators of patients with MAFLD,and can reduce the CAP and body quality index of patients,with high safety and significant therapeutic effect.
万方数据
维普
